Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 3/2014

Open Access 01-06-2014 | Research

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Authors: Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour K Majbour, Abdulmonem Al-Hayani, Omar MA El-Agnaf

Published in: Alzheimer's Research & Therapy | Issue 3/2014

Login to get access

Abstract

Introduction

The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD), compared with age-matched controls.

Methods

In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were evaluated by using well-established immunoassays.

Results

The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively. In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80.

Conclusions

The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with dementia compared with AD cases.
Appendix
Available only for authorised users
Literature
1.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, International AD: Global prevalence of dementia: a Delphi consensus study. Lancet. 2005, 366: 2112-2117. 10.1016/S0140-6736(05)67889-0.PubMedCentralCrossRefPubMed
2.
Blennow K, de Leon MJ, Zetterberg H: Alzheimer’s disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.CrossRefPubMed
3.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer’s disease. Lancet. 2011, 377: 1019-1031. 10.1016/S0140-6736(10)61349-9.CrossRefPubMed
4.
Eller M, Williams DR: alpha-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med. 2011, 49: 403-408.CrossRefPubMed
5.
Caballol N, Marti MJ, Tolosa E: Cognitive dysfunction and dementia in Parkinson disease. Mov Disord. 2007, 22: S358-S366. 10.1002/mds.21677.CrossRefPubMed
6.
Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T: Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important?. Brain. 2011, 134: 1493-1505. 10.1093/brain/awr031.PubMedCentralCrossRefPubMed
7.
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K: Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010, 9: 560-574. 10.1038/nrd3115.CrossRefPubMed
8.
Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6: 131-144. 10.1038/nrneurol.2010.4.CrossRefPubMed
9.
Perrin RJ, Fagan AM, Holtzman DM: Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009, 461: 916-922. 10.1038/nature08538.PubMedCentralCrossRefPubMed
10.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Initiative ADN: Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-413. 10.1002/ana.21610.PubMedCentralCrossRefPubMed
11.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5: 228-234. 10.1016/S1474-4422(06)70355-6.CrossRefPubMed
12.
Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011, 69: 570-580. 10.1002/ana.22311.PubMedCentralCrossRefPubMed
13.
Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T: Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2010, 81: 608-610. 10.1136/jnnp.2009.197483.CrossRefPubMed
14.
Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Widner H, Decraemer H, Nagga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012, 1-8.
15.
Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM: Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis. 2009, 16: 363-369.PubMed
16.
Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM: CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis. 2010, 22: 87-95.PubMed
17.
Noguchi-Shinohara M, Okuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M: CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res. 2009, 1251: 1-6.CrossRefPubMed
18.
Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM: Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain. 2009, 132: 1093-1101.CrossRefPubMed
19.
Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron. 2003, 37: 583-595. 10.1016/S0896-6273(03)00024-2.CrossRefPubMed
20.
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R: In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011, 108: 4194-4199. 10.1073/pnas.1100976108.PubMedCentralCrossRefPubMed
21.
Brown DR: Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life. 2010, 62: 334-339.PubMed
22.
Vekrellis K, Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L: Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011, 10: 1015-1025. 10.1016/S1474-4422(11)70213-7.CrossRefPubMed
23.
Sulzer D: Clues to how alpha-synuclein damages neurons in Parkinson’s disease. Mov Disord. 2010, 25: S27-S31. 10.1002/mds.22639.CrossRefPubMed
24.
Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW: Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson’s disease. J Clin Neurol. 2011, 7: 215-222. 10.3988/jcn.2011.7.4.215.PubMedCentralCrossRefPubMed
25.
Tokuda T, Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM: Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010, 75: 1766-1772. 10.1212/WNL.0b013e3181fd613b.CrossRefPubMed
26.
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B: Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007, 22: 1689-1707. 10.1002/mds.21507. quiz 1837CrossRefPubMed
27.
American Psychiatric Association, APA: Diagnostic and Statistical Manual of Mental Disorders. 1987, Washington, DC, 133-155. Third edition
28.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984, 34: 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed
29.
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005, 65: 1863-1872. 10.1212/01.wnl.0000187889.17253.b1.CrossRefPubMed
30.
El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006, 20: 419-425. 10.1096/fj.03-1449com.CrossRefPubMed
31.
Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P: Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson’s disease. Mov Disord. doi:10.1002/mds.25772. [Epub ahead of print]
32.
Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE: Heavy-chain complementarity-determining regions determine conformation selectivity of anti-abeta antibodies. Neurodegener Dis. 2011, 8: 117-123. 10.1159/000316530.CrossRefPubMed
33.
Sturgeon CM, Viljoen A: Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem. 2011, 48: 418-432. 10.1258/acb.2011.011073.CrossRefPubMed
34.
Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K: Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging. 2010, 31: 357-367. 10.1016/j.neurobiolaging.2008.03.027.CrossRefPubMed
35.
Sehlin D, Sollvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, Pettersson FE, Englund H: Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis. 2010, 21: 1295-1301.PubMed
36.
Meeus B, Verstraeten A, Crosiers D, Engelborghs S, Van den Broeck M, Mattheijssens M, Peeters K, Corsmit E, Elinck E, Pickut B, Vandenberghe R, Cras P, De Deyn PP, Van Broeckhoven C, Theuns J: LB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiol Aging. 2012, 33: 629-e5-629 e18CrossRefPubMed
37.
Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ, Cho J, Jeon BS: alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008, 70: 43-49. 10.1212/01.wnl.0000271080.53272.c7.CrossRefPubMed
38.
Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, Gasser T, Farrer MJ: Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007, 68: 916-922. 10.1212/01.wnl.0000254458.17630.c5.CrossRefPubMed
39.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997, 276: 2045-2047. 10.1126/science.276.5321.2045.CrossRefPubMed
40.
Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T: Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 1998, 152: 879-884.PubMedCentralPubMed
41.
Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005, 19: 164-170. 10.1159/000083178.CrossRefPubMed
42.
Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M: Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2006, 22: 200-208. 10.1159/000094871.CrossRefPubMed
43.
Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E: The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry. 2010, 26: 100-105.CrossRef
44.
Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ: Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathol. 2010, 120: 385-399. 10.1007/s00401-010-0723-9.PubMedCentralCrossRefPubMed
Metadata
Title
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Authors
Oskar Hansson
Sara Hall
Annika Öhrfelt
Henrik Zetterberg
Kaj Blennow
Lennart Minthon
Katarina Nägga
Elisabet Londos
Shiji Varghese
Nour K Majbour
Abdulmonem Al-Hayani
Omar MA El-Agnaf
Publication date
01-06-2014
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 3/2014
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/alzrt255

Other articles of this Issue 3/2014

Alzheimer's Research & Therapy 3/2014 Go to the issue

Research

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

Research

A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model

Review

Cerebral microbleeds: overview and implications in cognitive impairment

Commentary

PERK: a novel therapeutic target for neurodegenerative diseases?

Debate

Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer’s disease?

Research

The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease